We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Shire | LSE:SHP | London | Ordinary Share | JE00B2QKY057 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4,690.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
ZUG, Switzerland, May 19, 2017 /PRNewswire/ --
New clinical and real-life data in chronic hypoparathyroidism, to advance understanding of this rare disease and improve patients' lives
Shire plc (LSE: SHP, NASDAQ: SHPG), the global leader in rare diseases, announced today new research to be presented on rhPTH(1-84) and on the treatment and management of chronic hypoparathyroidism at the upcoming 19th Annual Meeting of the European Congress of Endocrinology (ECE), 20-23 May, Lisbon, Portugal. The data being shared provides valuable new insights into chronic hypoparathyroidism, including the long term treatment effect of rhPTH(1-84),[1] extensive global registry data on a number of disease related variables,[2] and patient-reported outcome (PRO) data on symptoms related to the disease from the Hypoparathyroidism Symptom Diary (HPT-SD).[3] These data demonstrate Shire's long term commitment to improving our understanding of this rare condition in order to further improve the lives of people living with chronic hypoparathyroidism.
Hypoparathyroidism is a rare endocrine disease that occurs when inadequate levels of parathyroid hormone (PTH) are secreted by the parathyroid glands, resulting in a mineral imbalance in the body expressed by a low concentration of calcium (hypocalcemia) and a high concentration of phosphate (hyperphosphatemia) in the blood.[4] Not adequately controlled hypoparathyroidism has a significant impact on patient well-being through physical, cognitive, and emotional symptoms.[5],[6] Chronic hypoparathyroidism is diagnosed in patients with a low concentration of calcium in the blood and inappropriately low PTH levels; for postsurgical chronic hypoparathyroidism, the features of hypoparathyroidism must persist for at least 6 months after surgery.[5],[7]
''Diseases like hypoparathyroidism are poorly understood because they are rare and lack both clinical and real-life data. We are absolutely committed to advancing the knowledge and understanding of the science of chronic hypoparathyroidism, and of patients' needs," said Dr John Germak, Global Medical Lead, Internal Medicine. "At ECE we will share new, important research about this rare condition with the scientific community. These new data are an important step forward for Shire to further our understanding of the disease so that we can continue to pursue better outcomes for people living with chronic hypoparathyroidism and other endocrine disorders."
At the congress, there will be three poster presentations on chronic hypoparathyroidism and two satellite symposia. Abstracts will be available on the ECE website at http://www.ece2017.org/ following the meeting.
Shire is dedicated to addressing challenges in chronic hypoparathyroidism, and will be sponsoring several symposia at the meeting:
Shire-sponsored symposia
- Perspectives on chronic hypoparathyroidism - the patient experience
Sunday 21st May, 14:00 - 15:15
- rhPTH(1-84) for patients with chronic hypoparathyroidism
Monday 22nd May, 14:00 - 15:15
NOTES TO EDITORS
About Shire
Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.
http://www.shire.com
Forward-Looking Statements
Statements included herein that are not historical facts, including without limitation statements concerning future strategy, plans, objectives, expectations and intentions, the anticipated timing of clinical trials and approvals for, and the commercial potential of, inline or pipeline products, are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, the following:
All forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by this cautionary statement. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Except to the extent otherwise required by applicable law, we do not undertake any obligation to update or revise forward-looking statements, whether as a result of new information, future events or otherwise.
References
©2017 Shire. All rights reserved.
SHIRE and the Shire Logo are registered trademarks of Shire Pharmaceutical Holdings Ireland Limited or its affiliates.
For further information, please contact:
Investor Relations
Ian Karp
ikarp@shire.com
+1-781-482-9018
Robert Coates
rcoates@shire.com
+44-1256-894874
Media
Annabel Cowper
annabel.cowper@shire.com
+41-44-878-6638
Debbi Ford
debbi.ford@shire.com
+1-617-949-9083
Copyright 2017 PR Newswire
1 Year Shire Chart |
1 Month Shire Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions